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POINT-COUNTERPOINT

Can Newly Developed, Rapid Immunochromatographic Antigen
Detection Tests Be Reliably Used for the Laboratory Diagnosis of
Influenza Virus Infections?
James J. Dunn,a Christine C. Ginocchiob,c
Department of Pathology, Texas Children’s Hospital, Houston, Texas, USAa; bioMérieux, Durham, North Carolina, USAb; Department of Pathology and Laboratory
Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, New York, USAc

Five years ago, the Point-Counterpoint series was launched. The initial article asked about the role of rapid immunochromatographic antigen testing in the diagnosis of influenza A virus 2009 H1N1 infection (D. F. Welch and C. C. Ginocchio, J Clin Microbiol 48:22–25, 2010, http://dx.doi.org/10.1128/JCM.02268-09). Since that article, not only have major changes been made in immunochromatographic antigen detection (IAD) testing for the influenza viruses, but there has also been rapid development of
commercially available nucleic acid amplification tests (NAATs) for influenza virus detection. Further, a novel variant of influenza A, H7N9, has emerged in Asia, and H5N1 is also reemergent. In that initial article, the editor of this series, Peter Gilligan,
identified two issues that required further consideration. One was how well IAD tests worked in clinical settings, especially in
times of antigen drift and shift. The other was the role of future iterations of influenza NAATs and whether this testing would be
available in a community hospital setting. James Dunn, who is Director of Medical Microbiology and Virology at Texas Children’s Hospital, has extensive experience using IAD tests for diagnosing influenza. He will discuss the application and value of
these tests in influenza diagnosis. Christine Ginocchio, who recently retired as the Senior Medical Director, Division of Infectious Disease Diagnostics, North Shore-LIJ Health System, and now is Vice President for Global Microbiology Affairs at bioMérieux, Durham, NC, wrote the initial counterpoint in this series, where she advocated the use of NAATs for influenza diagnosis. She will update us on the commercially available NAAT systems and explain what their role should be in the diagnosis of
influenza infection.

POINT

I

nfluenza virus infections are responsible for significant morbidity and mortality in both pediatric and adult populations worldwide. Unfortunately, diagnosis of influenza infection based solely
on clinical symptoms can be challenging in both pediatric and
adult patients (1-3). During periods of low influenza activity and
outside epidemic periods, patients may present with influenzalike illness (ILI) due to other circulating respiratory viruses. To
establish influenza as the viral etiology of infection requires accurate diagnostic testing, and the more rapidly that this result is
available, the more likely that clinical patient management will be
impacted. It is been shown that a timely and accurate diagnosis of
influenza infection will more likely result in initiation of antiviral
therapy, reduce the number of additional diagnostic studies, preclude the use of unnecessary antibiotics, and allow for prompt
institution of proper infection control practices (4).
Rapid influenza diagnostic tests (RIDTs) have been used extensively for many years in a variety of settings, including physicians’ offices, urgent care centers, and small laboratories where
more-complex viral diagnostic capabilities may not be available
(5). Generally speaking, positive results by these rapid methods
correlate well with actual influenza virus infection. Unfortunately,
the historic performance of these tests has been hampered by poor
sensitivity and low negative predictive values (NPVs) compared to
those of culture and/or molecular detection methods (6, 7), findings often more pronounced for novel or pandemic influenza virus strains (8-10). In light of these findings, several organizations
and professional societies have cautioned clinicians about the utility of RIDTs for certain patient populations and how results
should be interpreted (4, 11, 12). Most notably, because a negative
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RIDT result cannot reliably exclude influenza virus infection, follow-up testing with a more sensitive and specific method, such as
reverse transcription (RT)-PCR or viral culture, should be considered to confirm the result, a practice that can delay decisions about
patient management. Additionally, the correct interpretation and
appropriate use of RIDTs should be considered in the context of
the prevalence of circulating influenza strains in the community,
since this affects the positive and negative predictive values of the
tests. If the prevalence is unknown, RIDT results become difficult
to interpret and are of limited use in making patient management
decisions. Given the caveats and limitations that are associated
with use of traditional lateral-flow immunoassays, many laboratories have forgone their use or restricted testing to only certain
patient populations during periods of higher influenza prevalence. Ideally, if an RIDT had diagnostic accuracy approaching or
equivalent to those of the more sensitive methods, it could serve as
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a stand-alone method for the majority of patients presenting with
ILI. Hospitalized patients or those with underlying risk factors
that might predispose them to more-severe infection would still
require frontline or supplemental testing by other methods, as
recommended previously (4, 11, 12).
In an effort to overcome many of the issues associated with
RIDTs, two recently FDA-cleared, lateral-flow immunoassays
have been designed and developed to employ an instrumentbased digital scan of the test strip to enhance the sensitivity and
specificity of detection of influenza virus antigens. The Quidel
Sofia influenza A and B fluorescent immunoassay (FIA) (Sofia)
(Quidel Corp., San Diego, CA), FDA cleared in 2011, employs
europium-based immunofluorescence technology to qualitatively
detect and differentiate influenza A and B virus nucleoproteins
using the Sofia analyzer, an automated reader that scans the test
strip, measures the fluorescent signal, and processes the results
using method-specific algorithms in about 1 min. The BD Veritor
System for Flu A⫹B (Veritor) (BD Diagnostics, Sparks, MD),
FDA cleared in 2012, is an immunochromatographic assay for the
qualitative detection and differentiation of influenza A and B nucleoproteins using the BD Veritor System reader, a portable digital
instrument that uses a reflectance-based measurement to evaluate
the line signal intensities on the assay test strip and a proprietary
algorithm to identify and compensate for sample-related, nonspecific signal generation, a process requiring approximately 10 s.
Both test platforms eliminate the need for an operator to visualize
and interpret test results, a task that is often subjective, with varied
results.
In a number of studies published to date, both Sofia and Veritor displayed clinical sensitivities approaching those of culture
and/or RT-PCR for the detection of influenza A and B viruses.
Compared to R-Mix shell vial culture, Sofia displayed sensitivities
of 94% and 90% for influenza A and B, respectively, using nasopharyngeal (NP) aspirate/wash specimens, NP swabs, and nasal
swabs in a patient cohort that was predominantly ⬍6 years of age
(13). A second study evaluated the performance of Sofia compared to that of R-Mix culture using NP swabs collected from an
older group of patients (mean age, 27.7 years) and found sensitivities of 82% and 78% for influenza A and B viruses, respectively
(14). In both studies, the specificity of Sofia was ⬎95% for both
influenza A and B viruses. Some studies have shown sensitivities of
ⱖ90% for both influenza A and B virus detection using Sofia (15,
16) and Veritor (15, 17) compared to RT-PCR, while others have
found sensitivities in the range of 75% to 86% for Sofia (13, 18, 19)
and 69% to 88% for Veritor (17, 20). Some of the study-to-study
variability in performance might be attributed to several factors,
including the age of the patient, type of specimen collected, time of
collection relative to the onset of symptoms, and version of the test
used. For example, the use of some lots of Sofia kits were shown to
result in a significant number of falsely positive results, particularly for influenza B virus (15, 16), resulting in a manufacturer
recall of specific lots in December 2012 (21). In all studies in which
rapid antigen tests other than Sofia and Veritor were also included, both digitally read assays displayed significantly better
sensitivities for detecting influenza viruses (14, 15, 17, 18, 22). In
terms of workflow, once the sample is added to the test strip, Sofia
requires a 15-min incubation and Veritor requires a 10-min incubation. The time to process and test a single specimen or a small
batch, therefore, is much shorter overall using Veritor, a time
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frame similar to or slightly less than that using the BinaxNOW
influenza A&B assay (15, 17).
RIDTs have generally not performed well in detecting novel
and variant influenza A virus strains. Human infections with these
viruses have been a concern from both a public health perspective
and the perspective of managing individual patients. Sofia and
Veritor have demonstrated improved antigen detection capabilities in this area. An evaluation of FDA-cleared rapid antigen tests
to detect 7 different clinical isolates of influenza A variant H3N2
[(H3N2)v] virus showed that only four of seven assays, including
both Sofia and Veritor, detected all strains (23). Likewise, for the
novel avian origin influenza A (H7N9) virus, the limits of detection (LODs) were lowest for Veritor and Sofia among six rapid
antigen tests (24), and in serial respiratory specimens collected
from a patient with H7N9 infection, Veritor was positive in more
samples than four other rapid antigen assays, including Sofia and
the direct fluorescent-antibody assay (DFA) (25). In another
study, the LODs for influenza A (H7N9) virus for Veritor and
Sofia were ⬎1-log-fold dilution lower than those of five other
rapid antigen tests as well as two commercially available multiplex
molecular assays (26). The performance of both Sofia and Veritor
in the detection of 2009/pH1N1 strains has also shown improvement, with sensitivities ranging from 80% to 100% in clinical
studies (15, 17, 19, 20).
Clearly, these newer digital immunoassays (DIAs) are an upgrade over previous, commercially available lateral-flow immunoassays. To date, they have demonstrated enhanced sensitivity of
detection for seasonal, novel, and variant influenza strains, and as
a result, the negative predictive values have typically been ⬎90%
compared to those of RT-PCR in clinical studies. Generally speaking, the positive predictive values have been ⬎90%, except in
studies using Sofia performed around the time that specific lots
were recalled, a technical issue apparently rectified by the manufacturer. The DIAs are competitively priced at or below the list
prices of older RIDT platforms (⬃$15 to $22 per test), and in an
era when molecular testing for influenza viruses can cost upwards
of $100 per test, the ability to utilize a rapid and accurate immunochromatographic assay of this kind comes at a premium.
In light of the recent FDA proposal to increase the classification
of RIDTs from class I to class II devices subject to special control
and performance standards (27), it will be of interest to learn how
many different RIDTs remain commercially available in the next
few years. If adopted, this new rule would (i) identify the minimum acceptable performance criteria, (ii) identify the appropriate comparator for establishing the performance of new assays,
and (iii) call for mandatory annual analytical reactivity testing of
contemporary influenza strains, including testing of newly emerging strains that pose a danger of public health emergency. For
devices to be cleared for marketing and to remain on the market,
the performance criteria listed in Table 1 would be required, standards that few immunoassays currently fulfill. Even the DIAs described herein have widely varying performance characteristics
depending on the patient population being tested and the type of
specimen collected. It may be that FDA clearance of certain RIDTs
becomes limited to only certain age groups and sample types. For
the most part, the DIAs appear to consistently meet the criteria
and may be most useful when nasal wash/aspirate or NP swabs
from symptomatic pediatric patients are used for testing (13, 15,
17, 19), although the performance of Sofia in some cases was
skewed around the time of the recall (21). Undoubtedly, the land-
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TABLE 1 FDA-proposed minimal performance criteria for RIDTsa
% point estimate (lower 95%
CI) for:
Comparator

RIDT characteristic

Influenza A
virus

Influenza B
virus

Viral culture

Sensitivity
Specificity

ⱖ90 (ⱖ80)
ⱖ95 (ⱖ90)

ⱖ80 (ⱖ70)
ⱖ95 (ⱖ90)

Molecular assay

Sensitivity
Specificity

ⱖ80 (ⱖ70)
ⱖ95 (ⱖ90)

ⱖ80 (ⱖ70)
ⱖ95 (ⱖ90)

a

See reference 27. CI, confidence interval.
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future.
Since their introduction in the 1990s, RIDTs have been valued
for their ease of use, quick time to a result, and high positive
predictive value during periods of higher prevalence. However,
the poor sensitivity of many of these tests has been concerning,
since the misdiagnosis of influenza infection can have potentially
serious consequences. As laboratory experts, we have an obligation to provide accurate tests results, and implementation of
RIDTs that meet the new FDA criteria should provide clinicians
with reliable diagnostic information, reduce the likelihood of
false-negative results, and enable effective infection control and
public health responses during influenza outbreaks.
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COUNTERPOINT

T

he use of rapid influenza A/B direct tests (RIDTs) versus nucleic acid amplification tests (NAATs) was first debated in the
inaugural January 2010 Point-Counterpoint (1), in response to
reports of poor performance of RIDTs during the 2009 influenza
A H1N1 pandemic (pH1N1) (2, 3). Since 2009, the number of
U.S. Food and Drug Administration-cleared RIDTs has risen to 16
(4). Advantages of the newer RIDTs include improved yet variable
reactivity to circulating influenza strains and detection technologies with the potential to bridge the performance gap between
RIDTs and NAATs.
Are the newer RIDTs an improvement over the older RIDTs,
and are they more comparable to NAATs? A 2012 evaluation of 11
RIDTs by the U.S. Centers for Disease Control and Prevention
(CDC; Atlanta, GA) using dilutions of 23 circulating influenza A
and B virus strains demonstrated that the number of positive tests
varied by influenza type (A or B) and influenza A subtype (5).
Overall, there were no performance differences with influenza B
virus lineages. Conversely, there was high variability in the analytical results of the influenza A test among the strains tested, especially at lower viral concentrations. Additional studies have shown
that RIDT clinical sensitivity is less optimal for detection of
pH1N1 (55.8%) than for detection of H3N2 (71.0%) and the previous seasonal H1N1 strain (69.4%) due to their lower virus burden rather than a diminished capacity of the test to detect strains
(6, 7). A combination of lower analytical and clinical sensitivities
can have a significant impact on RIDT performance.
Two new immunofluorescence assays, the Sofia system for influenza A and B fluorescence immunoassay (Quidel, San Diego,
CA) and the Veritor System for Flu A⫹B (BD Diagnostics, Sparks,
MD), with automated reading, were developed to enhance performance. The assays were designed to detect the current strains influenza virus B/Victoria/Yamagata, pH1N1, and influenza virus A
(H3N2) and a variety of influenza A subtypes, including variations
of H2 to H9, H11 to H14, and H16, depending on the assay. Clinical trial performance data varied by specimen type and age of the
patients tested (8, 9). Compared to viral culture, Sofia demonstrated (in groups with ⱖ10 samples) sensitivities for influenza A
virus detection ranging from 78% (nasal swabs [NS]; patient ages,
22 to 59 years) to 99% (nasopharyngeal wash specimens/aspirates
[NPW/A]; patient age, ⬍6 years) and for influenza B virus detection ranging from 73% (NS; patient ages, 22 to 59 years) to 94%
(NP swabs [NPS]; patient ages, 6 to 21 years) (8). Compared to
values for an FDA-cleared RT-PCR assay in the prospective arm of
the Veritor clinical trial study, the percentages of positive agreement for influenza A ranged from 81.3% (NPS) to 83% (NPW/A)
and for influenza B ranged from 81.3% (NPS) to 85.6% (NPW/A)
(9). Both assays demonstrated high specificities for influenza A
and B. However, the overall performance of both assays was heavily weighted by patient age, a factor known to effect assay performance, since younger patients shed larger amounts of virus and
for longer periods, whereas geriatric patients show the lowest viral
titers. In total, 96% of samples tested with Sophia and 77% tested
with Veritor were from patients ⬍22 years old, and only 1% of the
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samples tested by Sophia and 0.1% tested by Veritor were from
patients ⱖ60 years. Therefore, assay performance was not well
established for an advanced age group that has the highest rates of
influenza-associated morbidity and mortality. Gao et al. evaluated
the effect of age on the clinical sensitivity of other RIDTs in comparison to RT-PCR and demonstrated that increasing age was
negatively associated with RIDT sensitivity (⬍2 years, 85.7%; 2 to
39 years, 60.3%; ⱖ40 years, 33.3%) (10).
Independent studies compared the performances of Sophia
and Veritor to those of other RIDTs, using either NAAT or NAAT
plus viral culture as the reference methods (11–16). Sophia testing
yielded sensitivities for influenza A and B virus detection ranging
from 78.9% to 95.8% and 62.5% to 98.1%, respectively (11–14),
whereas nonfluorescent RIDTs demonstrated sensitivities for influenza A and B virus detection ranging from 54.8% to 79.2% and
40.7% to 97.3%, respectively. Veritor sensitivities for influenza A
and B virus detection ranged from 72.0% to 93.8% and 69.3% to
94.2%, respectively, whereas nonfluorescent RIDTs demonstrated
sensitivities for influenza A and B virus detection ranging from
56.0% to 85.7% and 57.3% to 80.8%, respectively (14–16). The
sensitivities of Sophia and Veritor were better than those of some
RIDTs, were inferior to those of NAATs, and varied depending on
the influenza strain, specimen type, and patient population, with
pediatric studies yielding the best results.
Another CDC study evaluated seven RIDTs, including Sophia
and Veritor, in comparison to the CDC Flu rRT-PCR Dx panel
(CDC) for detection of an influenza A (H3N2) virus variant
(H3N2v) (17). Four of seven RIDTs (Directigen EZ Flu A⫹B
[BD], Sofia, Veritor, and Xpect Flu A&B [Remel, Lenexa, KS])
detected all seven H3N2v strains, BinaxNOW influenza A&B (Alere, Waltham, MA) detected five of seven strains, Quick View
Influenza A⫹B test (Quidel) detected three of seven strains, and
SAS FluAlert A&B (SA Scientific, San Antonio, TX) detected only
one strain. This study highlights the variable performances of
RIDTs for emerging strains, indicating that several viruses and
subtypes should be evaluated with each RIDT on a regular basis.
Currently, RIDT manufacturers are not required to reevaluate the
performance of their assays once they are FDA cleared. However,
the emergence of novel or variant influenza strains requires a
more stringent oversight of RIDTs to provide reasonable assurance of the safety and effectiveness of RIDTs. Consequently, the
FDA has proposed that all RIDTs regulated under §866.3330 of
the Code of Federal Regulations (18) be reclassified as class II with
special controls. This would include mandatory annual analytical
reactivity testing of contemporary influenza strains, including
newly emerging strains that pose a danger to public health.
Despite the suboptimal performance of RIDTs, studies have
shown that RIDTs improve seasonal influenza diagnostic sensitivity above unaided clinical diagnosis and affects clinical decisionmaking, thereby reducing diagnostic testing, antibiotic use, and
emergency department utilization while increasing antiviral prescription rates (19).
If these benefits are realized for RIDTs, why would we not want
to use more sensitive and specific NAATs in lieu of RIDTs to
further enhance the above-named benefits? Currently, there are
26 FDA-cleared NAATs for the detection of influenza A and B (4).
Please refer to Table 1 in the CDC reference (20) for specifics on
each assay and reviews (21, 22), as a comprehensive overview is
beyond the scope of this commentary. Eleven assays detect influenza A and B, without influenza A virus subtyping, eight assays
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detect influenza A and B, with influenza A virus subtyping, six
detect just influenza A, with subtyping, and one detects influenza
B virus, with subtyping. Ten assays detect additional respiratory
viruses (1 to 15), and one assay detects three additional bacterial
pathogens, allowing for a more comprehensive syndromic diagnostic screening. NPS, preferably flocked swabs, since they have
been demonstrated to collect more cellular material, are approved
for all tests, with various additional sample types, including NS,
NPW/A, tracheal aspirates, and lower respiratory tract specimens
(LRTS), approved depending on the test (20). Virus detection in
LRTS is essential in severe cases of pneumonia since upper respiratory tract samples may test negative. NAAT clinical performance has been consistently better than those of RIDTs, including
those developed after 2009, when used in a variety of clinical settings and patient populations (2, 3, 9, 10, 21, 22). NAAT sensitivities range from 90.5% to 97.6%, thereby improving the diagnosis,
especially in older patients and if suboptimal samples are collected. The majority of studies demonstrate a specificity close to
100% (21, 22), providing confidence in a positive result, especially
outside the influenza season.
Considering the limitations of RIDTs and the better performance of NAATs, I pose several questions relating to test features
which are consistently used to promote the use of RIDTs. These
include questions related to ease of use, rapid turnaround time,
and low cost compared to those of NAATs. Finally, I question the
argument that the detection of influenza A or B is sufficient since
there no treatments for other respiratory viruses and their identification does not necessarily change patient management.
Are RIDTs easier to perform than all NAATs? NAATs vary in
format (although all include steps to extract, amplify, and detect
nucleic acid), ease of use (hands-on times, 2 min to several hours),
and times to results (⬍30 min to 8 or more hours). The only FDA
CLIA-waived NAAT, the Alere iNAT FluA/B (Alere, Waltham,
MA), takes approximately 15 min to perform. The Liat Influenza
A/B assay (IQuum, Marlborough, MA) has a ⬍30-min test time,
the Xpert Flu assay (Cepheid, Sunnyvale, CA) and the FilmArray
RP assay (BioFire/bioMérieux, Salt Lake City, UT) provide results
in approximately 1 h, and the Simplexa FluA/B⫹RSV Direct assay
(Focus Diagnostics, 3M, Cyprus, CA) provides results in ⬍2 h. All
four NAATs, like RIDTs, require minimal hands-on time (one
step and less than 2 min to perform), and they are listed as being of
moderate complexity. The Verigene respiratory virus nucleic acid
test and Verigene respiratory virus plus nucleic acid test (Nanosphere, Northbrook, IL) are also listed as being of moderate complexity, with results in 3.5 h and a minimal 2-step process (addition of sample and reading of results).
Is a 15-min RIDT with a 72% to 85% sensitivity better for
facilitating rapid patient care than a 98%-sensitive NAAT with a
15- to 60-min time to results? A very minimal gain in the time to
results cannot justify an incorrect or missed diagnosis. Diagnostic
accuracy has been shown to reduce ancillary testing, assist in decisions to admit or not admit, and facilitate appropriate therapeutic decisions (antiviral, antibiotic, or none). Incorrect treatment is
expensive and can result in greater risk of toxicity, adverse effects,
and development of drug resistance (21–23). Optimal test performance is essential for infection control to reduce the risk of nosocomial outbreaks and their associated morbidity and mortality
and to reduce the significant costs to health care systems, including health care worker (HCW) absenteeism, medication costs, and
staff time spent in outbreak control. Yassi et al. investigated an
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influenza A outbreak that resulted in infection of 17 HCWs (34%
servicing the ward) and 16 chronic geriatric patients (47% of patients), of whom 3 died (24). Another study relating to an influenza A H3N2 outbreak among geriatric patients and HCWs identified six nosocomial infections and three independent clusters,
with an HCW source identified in at least two (25). Nosocomial
outbreaks of influenza/parainfluenza have been significantly associated (P ⫽ ⬍0.001) with complete closure of medical units (26).
Outbreaks are especially dangerous for immunocompromised patients, for whom there is a risk of prolonged shedding and development of oseltamivir resistance. An outbreak in a hematologic/
oncologic unit resulted in 23/76 patients (32%) developing
nosocomial influenza, three patients being identified with oseltamivir-resistant virus, and 3 patients expiring (27). An outbreak
investigation in the Netherlands found nosocomial transmission
of oseltamivir-resistant virus, leading to three cases of pneumonia
and two mortalities (28).
Is the detection of just influenza A and/or B by RIDTs sufficient
in a hospitalized patient, especially since antiviral treatment is
available only for influenza? Despite the fact that treatment is limited to influenza, identification of other respiratory viruses as the
cause of disease will reduce unnecessary use of antivirals and antibiotics, promoting good stewardship practices. A study by Rodgers et al. found that use of a rapid comprehensive respiratory
panel that detected 21 viruses and 3 bacterial pathogens resulted is
significant improvements by reducing the mean time to results,
increasing the percentage of patients in the emergency department (ED) with a result, and shortening the duration of antibiotic
use if results were provided within 4 h (23). A positive result decreased inpatient length of stay and time in isolation. Additionally,
one must consider the potential for mixed viral infections and the
impact of cohorting during a busy respiratory season. One study
identified coinfections with other respiratory viruses in 7.2% of
patients with influenza (29), and another study found that 3.39%
of all specimens and 9.55% of all positive specimens contained
more than one virus, with influenza virus present in 52.17% of the
mixed infections (30). A secondary viral infection in an alreadycompromised patient can result in severe outcomes.
Most NAATs can subtype influenza A virus strains. This is
important for surveillance and to identify potential new variants.
Testing positive for influenza A matrix but negative for the current
hemagglutinin types would result in an “unsubtypeable” strain, as
was the case with pH1N1 (31). Subtyping may be relevant for
treatment, as different subtypes can have different antiviral drug
susceptibilities, as noted with prepandemic seasonal influenza
A(H1N1), which was oseltamivir resistant whereas the cocirculating H3N2 strain was susceptible. Although in the 2013-2014 season, 98.2% of pH1N1, 100% of H3N2, and 100% of influenza B
virus strains were oseltamivir susceptible, pH1N1 oseltamivir resistance occurred, and under these conditions, if resistant subtypes predominate, subtyping would be essential (32).
Is performing an inexpensive RIDT (average cost, $10 to $15)
really less expensive than performing NAATs? The cost of a NAAT
can range from approximately $40 to $150 or more. A RIDT
would be less expensive in an outreach setting if no further testing
was required. However, for inpatients or for persons at risk for
severe disease, in accordance with CDC guidelines, negative sample results for a patient suspected of having influenza should be
reflexed to more-sensitive methodologies, such as viral culture
and NAAT, with significant additional testing costs and a delay in

Journal of Clinical Microbiology

June 2015 Volume 53 Number 6

Point-Counterpoint

the time to results. Delays in results lead to additional ancillary
testing and prolonged hospital stays. The study by Rodgers et al.
determined that a positive viral test result decreased the inpatient
length of stay and time in isolation (23). Cost savings were estimated at $231 in hospital costs, $17 in antibiotic usage per patient,
and $178 per patient for testing if a panel of various PCRs had to
be run in lieu of the single rapid comprehensive respiratory panel.
The extra cost of a NAAT can be justified by the prevention of
nosocomial outbreaks with significant impact on hospital finances, particularly if an entire ward must be closed, HCWs must
be furloughed, and patients must receive antiviral prophylaxis.
Have RIDTs, compared to NAATs, improved to an extent that
we should support their use alone or as a primary screening test in
all clinical settings? Better-performing RIDTs could be used under
circumstances of financial constraint, in circumstances where
there are no other options, in appropriate outpatient and ED discharge settings for specific patient populations, such as nonimmunocompromised pediatric patients, and when only influenza is
documented in the community. Even in these settings, clinicians
must be aware that RIDT performances are not equivalent among
all tests for all strains, and manufacturer claims do not necessarily
reflect real performance that correlates with sample type, time of
sample collection, and virus burden (33). Despite the known poor
sensitivities of some RIDTs or a lack of knowledge about their
performance in community settings, Williams et al. found that
clinicians in outpatient settings often relied on RIDTs for deciding
antiviral therapy rather than following CDC recommendations
for patients at higher risk for complications (34). Many clinicians
do not follow the CDC recommendations for reflex testing to
confirm positive results when the prevalence of influenza is low or
when the test is negative for a patient highly suspected of having
influenza and/or with an increased risk for severe disease when
disease prevalence is high. For hospitalized patients, only NAATs
should be performed, preferably with a comprehensive respiratory panel. Additionally, monitoring of critically ill patients using
a quantitative NAAT has been shown to help evaluate responses to
antiviral therapy. Performing a one-step NAAT is as simple as
performing a RIDT, can be performed on demand 24 h a day/7
days per week, in all-size laboratories, with minimal technical expertise required. A missed diagnosis can have a significant impact
on patient clinical outcome and a financial impact on laboratory
services and the utilization of health care resources.
Christine C. Ginocchio
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SUMMARY
Points of agreement
Many of the points of agreement from the 2010 influenza Point-Counterpoint remain unchanged.
• Influenza NAATs have sensitivities superior to those of RIDTs for influenza viruses. Negative RIDT results require confirmation
by NAATs or culture.
• RIDTs are best done in the pediatric population early in the disease course during periods of high influenza disease activity.
• Rapid diagnostic tests by either RIDTs or NAATs reduce ancillary test utilization, inappropriate use of antibacterial agents, and
appropriate use of influenza-specific antivirals.
New points of agreement
• The new digital immunoassays for the detection of influenza A and B viruses have performances superior to those of other
influenza immunochromatographic assays, with similar turnaround times. In particular, they can detect newly emergent influenza strains, such as influenza A 2009/pH1N1, novel H3N2 variants, and H7N9.
• Diagnosis of respiratory infections in hospitalized and/or immunocompromised patients is best accomplished using NAAT
panels, which can detect multiple viral and bacterial pathogens.
• Newer NAATs have reduced turnaround times approaching those of the influenza DIAs and greater accuracy, which may obviate
the use of DIAs.
Issues to be resolved
• Studies of the influenza DIAs are needed in the geriatric age groups (⬎60 years old), the population of patients who suffer the
highest morbidity and mortality from influenza.
• Strict performance criteria for influenza RIDTs are likely to be instituted by the Food and Drug Administration. In particular,
failure to meet annual performance standards based on currently circulating viral genotypes may result in some RIDTs being
removed from the marketplace. Performance standards may also limit the patient populations or the specimen types that are
approved for testing.
Peter H. Gilligan, Editor, Journal of Clinical Microbiology
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